Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.

@article{Dotan2014PatientFT,
  title={Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study.},
  author={Iris Dotan and Yulia Ron and H Yanai and Stuart D. Becker and Sigal Fishman and Lior Yahav and Merav Ben Yehoyada and Diane R Mould},
  journal={Inflammatory bowel diseases},
  year={2014},
  volume={20 12},
  pages={
          2247-59
        }
}
BACKGROUND Infliximab (IFX) is effective therapy for ulcerative colitis and Crohn's disease, but it may be associated with side effects and loss of response. One loss of response mechanism is increased IFX clearance (IFX-CL), resulting in short half-life and decreased troughs. METHODS Patients were recruited, and relevant demographic, clinical, and laboratory data were recorded. IFX serum concentrations and antibodies against IFX (ATI) were measured for therapeutic drug monitoring and modeled… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 13 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 42 extracted citations

Similar Papers

Loading similar papers…